These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455 [TBL] [Abstract][Full Text] [Related]
32. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Janicak PG; Javaid JI; Sharma RP; Leach A; Dowd S; Davis JM Acta Psychiatr Scand; 1997 Apr; 95(4):343-50. PubMed ID: 9150830 [TBL] [Abstract][Full Text] [Related]
33. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Balant-Gorgia AE; Eisele R; Balant L; Garrone G Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392 [TBL] [Abstract][Full Text] [Related]
34. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. Ko GN; Korpi ER; Kirch DG J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607 [TBL] [Abstract][Full Text] [Related]
36. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. Gattaz WF; Rost W; Hübner CK; Bauer K Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996 [TBL] [Abstract][Full Text] [Related]
37. Effect of propranolol treatment on serum prolactin level in schizophrenic patients. Elizur A; Segal Z; Yeret A; Ben-David M Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751 [No Abstract] [Full Text] [Related]
38. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. Hollister LE; Kim DY Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396 [TBL] [Abstract][Full Text] [Related]
39. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. Darby JK; Pasta DJ; Dabiri L; Clark L; Mosbacher D J Clin Psychopharmacol; 1995 Oct; 15(5):334-40. PubMed ID: 8830064 [TBL] [Abstract][Full Text] [Related]
40. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]